S2Medical (S2M) H1 2026 earnings summary

Executive summary

• Net sales for the first half of 2026 increased to 7.4 MSEK from 6.9 MSEK year-over-year, driven by higher sales through the Abena partnership and core products.

• Operating result improved to 0.2 MSEK from -0.5 MSEK, reflecting cost optimizations and lower external costs.

• Net profit for the period was 0.2 MSEK, unchanged from the previous year.

• The company maintained a cost-neutral operation while advancing its technology and product portfolio.

Financial highlights

• Net sales: 7.4 MSEK (up from 6.9 MSEK year-over-year).

• Operating result: 0.2 MSEK (improved from -0.5 MSEK year-over-year).

• Net profit: 0.2 MSEK (unchanged year-over-year).

• Earnings per share: 0.00 SEK (unchanged year-over-year).

• Cash flow for the period: -0.3 MSEK (down from 0.3 MSEK year-over-year).

• Cash and cash equivalents at period end: 0.6 MSEK.

• Equity ratio at period end: 60%.

Outlook and guidance

• The company aims to leverage its validated patent portfolio and product pipeline for future growth.

• Proceeds from the upcoming rights issue will be used to accelerate revenue-generating activities and product development.